---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027837"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-06-09T11:00:23+00:00"
generated_at: "2026-06-09T11:06:40.850221+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Lee and Martin

## Summary
- James Sapirstein appointed CEO effective June 3, 2026; prior CEO of Entero Therapeutics (Nasdaq: ENTO).
- Sam Lee remains President and Chief Scientific Officer; James Martin remains CFO.
- Sapirstein receives $265,000 base salary, 50% target bonus, and initial option grant of 235,000 shares at $1.05 vesting over 4 years.
- Additional 235,000 options may be granted on 6-month anniversary subject to performance and board approval.

## SEC filing metadata
- accession: 0001493152-26-027837
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-06-09T11:00:23+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027837
- JSON: https://secwatch.observer/filing/0001493152-26-027837.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027837.txt

## Key facts
- Executive change
  James Martin departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..
  - Action: replaced
  - Role: Co-Chief Executive Officer
  source text: Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm
- Executive change
  Sam Lee departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..
  - Action: replaced
  - Role: Co-Chief Executive Officer
  source text: Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm
- Executive change
  James Sapirstein was appointed as Chief Executive Officer at Cocrystal Pharma, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/0001493152-26-027837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.